Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 24951-24960 Newer>

The Motley Fool July 30, 2007 Tom Taulli	Compuware Needs a Makeover The enterprise software developer suddenly realizes that its sales force requires a serious overhaul. What will this mean to shareholders?
The Motley Fool July 30, 2007 Ryan Fuhrmann	3M Bucks the Trend Given its track record, it's hard to argue against 3M, and judging by a recently cranky Mr. Market, more investors may be heading into 3M's stable arms.
The Motley Fool July 30, 2007 Tom Taulli	Back to Callidus The enterprise software company continues its revenue ramp, but can't seem to make a profit -- yet. Investors, take note.
The Motley Fool July 30, 2007 Rich Smith	General Dynamics Caught in a Firefight The market downturn erases gains. However, investors in General Dynamics know that what matters in investing for the long-term is not the day-to-day gyrations of the digits attached to a ticker symbol, but the performance of the business that symbol represents.
The Motley Fool July 30, 2007 Dave Mock	No Frills or Chills From Alaska Communications Solid results are delivered by the Alaskan telecom. ACS will face a new challenge in the Alaskan market next year, however -- one that may provide formidable competition.
The Motley Fool July 30, 2007 Dave Mock	Foolish Forecast: Navteq's Guiding Light The mapping software maker is set to report second-quarter earnings results. Investors, here is what you can expect to see.
The Motley Fool July 30, 2007 Tim Beyers	The Applix of My Eye If it pays to be greedy when others are fearful, then it's time to load up on business analytics software provider Applix. The stock was down more than 10%.
The Motley Fool July 30, 2007 Tom Taulli	Lawson Rakes in More Dough The enterprise software operator continues to gain ground on Oracle and SAP. Investors, take note.
The Motley Fool July 30, 2007 Tom Taulli	Investors Don't Read Voltaire Facing tough competition, the data center technology company couldn't muster much interest in its IPO.
The Motley Fool July 30, 2007 Brian Lawler	Amgen Adjusting Amgen's second quarter reflects the pain it's feeling with its top drugs. Investors, take note.
<Older 24951-24960 Newer> Return to current articles.